Targeting the inflammation in HCV-associated hepatocellular carcinoma: A role in the prevention and treatment

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Castello, Giuseppe ^a   Costantini, Susan ^a   Scala, Stefania ^b  

^a Oncology Research Centre of Mercogliano (CROM)   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACACIA NILOTICA EXTRACT; ALITRETINOIN; ALPHA TOCOPHEROL; ANGIOPEPTIN; BUTYRIC ACID; CHEMOKINE; CURCUMIN; CYTOKINE; FLAVONOID; GALLIC ACID; GREEN TEA EXTRACT; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; POLYPHENOL; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; RETINOID; S ADENOSYLMETHIONINE; SELENIUM; SORAFENIB; STEROID 5ALPHA REDUCTASE INHIBITOR; SULINDAC; TRASTUZUMAB; TRIBUTYRIN; UNINDEXED DRUG; VALPROIC ACID; VITAMIN D; XANTHOHUMOL; YTTRIUM 90;

CANCER PREVENTION; CANCER THERAPY; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; DRUG TARGETING; HEPATITIS C VIRUS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER NODULE; LIVER TUMOR; MALIGNANT TRANSFORMATION; NONHUMAN; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; HEPATITIS C; IMMUNOLOGY; INNATE IMMUNITY; OXIDATIVE STRESS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; HEPATITIS C; HUMANS; IMMUNITY, INNATE; LIVER NEOPLASMS; OXIDATIVE STRESS;

EID: 78049324216     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-109     Document Type: Review

References (110)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005. J Clin Oncol 2009, 27(9):1485-91. 10.1200/JCO.2008.20.7753, 2668555, 19224838.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics 2007. CA Cancer J Clin 2007, 57(1):43-66. 10.3322/canjclin.57.1.43, 17237035.
3. El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology 2007, 132(7):2557-76. 10.1053/j.gastro.2007.04.061, 17570226.
4. Castello G, Scala S, Palmieri G, Curley SA, Izzo F. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol 2010, 134(3):237-50. 10.1016/j.clim.2009.10.007, 19910258.
5. Fassio E. Hepatitis C and hepatocellular carcinoma. Ann Hepatol 2010, 9:119-22.
6. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008, 48(1):137-45. 10.1002/hep.22312, 18537177.
7. Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C, Scognamiglio P, Pisanti FA, Solmone M, Di Cicco P, Ippolito G, Franceschi S, Serraino D. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer 2008, 44(6):847-53. 10.1016/j.ejca.2008.01.025, 18313290.
8. Ryder SD. British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003, 52:1-8. 10.1136/gut.52.suppl_3.iii1, 1773527, 12477745.
9. Nash KL, Woodall T, Brown AS, Davies SE, Alexander GJ. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. World J Gastroenterol 2010, 16(32):4061-5. 10.3748/wjg.v16.i32.4061, 2928460, 20731020.
10. Chiesa R, Donato F, Tagger A, Favret M, Ribero ML, Nardi G, Gelatti U, Bucella E, Tomasi E, Portolani N, Bonetti M, Bettini L, Pelizzari G, Salmi A, Savio A, Garatti M, Callea F. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiology, Biomarkers & Prevention 2000, 9:213-6.
11. Anzola M. Hepatocellular Carcinoma: Role of Hepatitis B and Hepatitis C Viruses Proteins in Hepatocarcinogenesis. J Viral Hepat 2004, 11(5):383-93. 10.1111/j.1365-2893.2004.00521.x, 15357643.
12. Paterlini-Bréchot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D, Bréchot C. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22:3911-3916. 10.1038/sj.onc.1206492, 12813464.
13. Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. J Clinical Virology 2005, 34:S75-S78.
14. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436(7053):946-52. 10.1038/nature04079, 16107834.
15. Ueno Y, Sollano JD, Farrell GC. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol 2009, 24(4):531-6. 10.1111/j.1440-1746.2009.05814.x, 19368633.
16. Tosi MF. Innate immune responses to infection. J Allergy Clin Immunol 2005, 116(2):241-9. 10.1016/j.jaci.2005.05.036, 16083775.
17. Li Z, Diehl AM. Innate immunity in the liver. Curr Opin Gastroenterol 2003, 19(6):565-71. 10.1097/00001574-200311000-00009, 15703606.
18. Norris S, Collins C, Doherty DG, Smith F, McEntee G, Traynor O, Nolan N, Hegarty J, O'Farrelly C. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 1998, 28(1):84-90. 10.1016/S0168-8278(98)80206-7, 9537869.
19. Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gastroenterology 2001, 120(1):250-60. 10.1053/gast.2001.20947, 11208734.
20. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119(7):1745-54. 10.1172/JCI39133, 2701885, 19587449.
21. Thompson JM, Iwasaki A. Toll-like receptors regulation of viral infection and disease. Adv Drug Deliv Rev 2008, 60(7):786-94. 10.1016/j.addr.2007.11.003, 2410298, 18280610.
22. Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436(7053):939-45. 10.1038/nature04078, 16107833.
23. Zhang X, Dou J, Germann MW. Characterization of the cellular immune response in hepatitis C virus infection. Med Res Rev 2009, 29(6):843-66. 10.1002/med.20157, 19378287.
24. Sklan EH, Charuworn P, Pang PS, Glenn JS. Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol 2009, 6(4):217-27. 10.1038/nrgastro.2009.32, 19347013.
25. Kanto T, Hayashi N. Innate immunity in hepatitis C virus infection: Interplay among dendritic cells, natural killer cells and natural killer T cells. Hepatol Res 2007, 3:S319-26.
26. Takahashi K, Asabe S, Wieland S, Garaigorta U, Gastaminza P, Isogawa M, Chisari FV. From the Cover: Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. PNAS 2010, 107(16):7431-7436. 10.1073/pnas.1002301107, 2867703, 20231459.
27. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol 2010,
28. Canning C, O'Brien M, Hegarty J, O'Farrelly C. Liver immunity and tumour surveillance. Immunol Lett 2006, 107(2):83-8. 10.1016/j.imlet.2006.07.002, 17101177.
29. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001, 194(10):1395-406. 10.1084/jem.194.10.1395, 2193681, 11714747.
30. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002, 99(24):15661-8. 10.1073/pnas.202608299, 137773, 12441397.
31. Jinushi M, Takehara T, Kanto T, Tatsumi T, Groh V, Spies T, Miyagi T, Suzuki T, Sasaki Y, Hayashi N. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 2003, 170(3):1249-56.
32. Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001, 97(10):3171-6. 10.1182/blood.V97.10.3171, 11342445.
33. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, Romics L, Mandrekar P, Zapp M, Szabo G. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 2003, 170(11):5615-24.
34. Masuzaki R, Yoshida H, Omata M. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Oncology 2010, 78:17-23. 10.1159/000315225, 20616579.
35. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001, 19:65-91. 10.1146/annurev.immunol.19.1.65, 11244031.
36. Frese M, Schwärzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35(3):694-703. 10.1053/jhep.2002.31770, 11870386.
37. Durante-Mangoni E, Wang R, Shaulov A, He Q, Nasser I, Afdhal N, Koziel MJ, Exley MA. Hepatic CD1 d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol 2004, 173(3):2159-66.
38. Wiltrout RH. Regulation and antimetastatic functions of liver associated natural killer cells. Immunol Rev 2000, 174:63-76. 10.1034/j.1600-0528.2002.00014h.x, 10807507.
39. De Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, Nuti S, Colombo M, Callea F, Porcelli SA, Panina-Bordignon P, Abrignani S, Casorati G, Dellabona P. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 2004, 173(2):1417-25.
40. Grüner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, Zachoval R, Santantonio T, Cucchiarini M, Cerny A, Pape GR. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000, 181(5):1528-36. 10.1086/315450, 10823750.
41. Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, Chung RT, Walker BD. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002, 76(24):12584-95. 10.1128/JVI.76.24.12584-12595.2002, 136690, 12438584.
42. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000, 6(5):578-82. 10.1038/75063, 10802716.
43. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000, 191(9):1499-512. 10.1084/jem.191.9.1499, 2213430, 10790425.
44. Grasl-Kraupp B, Rossmanith W, Ruttkay-Nedecky B, Müllauer L, Kammerer B, Bursch W, Schulte-Hermann R. Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia. Hepatology 1998, 28(3):717-26. 10.1002/hep.510280318, 9731564.
45. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003, 38(6):1437-48.
46. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, Nelson DR. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40(5):1062-71. 10.1002/hep.20454, 15486925.
47. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, Blum HE, von Weizsäcker F, Thimme R. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005, 79(12):7860-7. 10.1128/JVI.79.12.7860-7867.2005, 1143651, 15919940.
48. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005, 65(6):2457-64. 10.1158/0008-5472.CAN-04-3232, 15781662.
49. Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY, Lee SD. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi (Taipei) 1999, 62(6):327-33.
50. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006, 80(6):1197-213. 10.1189/jlb.0506297, 16946019.
51. Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa Y, Kinoshita H, Yamakado M, Kato N, Shiina S, Omata M. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: An analysis based on gender differences. Int J Cancer 2009, 125(10):2264-9. 10.1002/ijc.24720, 19585572.
52. Capone F, Costantini S, Guerriero E, Calemma R, Napolitano M, Scala S, Izzo F, Castello G. Cytokine serum levels in patients with hepatocellular carcinoma. Eur Cytok Net 2010, 21(2).
53. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006, 387(4):349-60. 10.1515/BC.2006.047, 16606331.
54. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007, 121(11):2381-6. 10.1002/ijc.23192, 17893868.
55. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003, 3(4):276-85. 10.1038/nrc1046, 12671666.
56. Muriel P. Role of free radicals in liver diseases. Hepatol Int 2009, 3(4):526-36.
57. Pal S, Polyak SJ, Bano N, Qiu WC, Carithers RL, Shuhart M, Gretch DR, Das A. Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol 2010, 25(3):627-34. 10.1111/j.1440-1746.2009.06128.x, 20074151.
58. Farinati F, Cardin R, Bortolami M, Burra P, Russo FP, Rugge M, Guido M, Sergio A, Naccarato R. Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J Viral Hepat 2007, 14(12):821-9.
59. Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, Fujii H, Rusyn I. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 2007, 14(3):1182-90. 10.1245/s10434-006-9049-1, 17195915.
60. Adelman R, Saul RL, Ames BN. Oxidative damage to DNA: relation to species metabolic rate and life span. Proc Natl Acad Sci USA 1988, 85(8):2706-8. 10.1073/pnas.85.8.2706, 280067, 3128794.
61. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 2000, 95(4):1041-50. 10.1111/j.1572-0241.2000.01979.x, 10763957.
62. Konishi M, Iwasa M, Araki J, Kobayashi Y, Katsuki A, Sumida Y, Nakagawa N, Kojima Y, Watanabe S, Adachi Y, Kaito M. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol 2006, 21(12):1821-5. 10.1111/j.1440-1746.2006.04420.x, 17074020.
63. Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, Niiyama G, Ikeda H, Hanano S, Suehiro M, Togawa K, Yamada G. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid Redox Signal 2004, 6(1):19-24. 10.1089/152308604771978318, 14713333.
64. Hara Y, Hino K, Okuda M, Furutani T, Hidaka I, Yamaguchi Y, Korenaga M, Li K, Weinman SA, Lemon SM, Okita K. Hepatitis C virus core protein inhibits deoxycholic acidmediated apoptosis despite generating mitochondrial reactive oxygen species. J Gastroenterol 2006, 41(3):257-68. 10.1007/s00535-005-1738-1, 16699860.
65. Seronello S, Sheikh MY, Choi J. Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Radic Biol Med 2007, 43(6):869-82. 10.1016/j.freeradbiomed.2007.05.036, 17697932.
66. Choi SH, Hwang SB. Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. J Biol Chem 2006, 281(11):7468-78. 10.1074/jbc.M512438200, 16407286.
67. Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RL, Larson AM, Yeh MM, Camp DG, Smith RD, Katze MG. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 2007, 46(3):649-57. 10.1002/hep.21751, 17654742.
68. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 25(27):3834-47. 10.1038/sj.onc.1209562, 16799625.
69. Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH. Use of Yttrium-90 Microspheres in Patients with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis. J Vasc Interv Radiol 2010, 21(9):1377-1384. 10.1016/j.jvir.2010.04.027, 20691606.
70. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 2010, 36(1):43-53. 10.1016/j.ctrv.2009.10.002, 19910122.
71. Pirola L, Fröjdö S. Resveratrol: one molecule, many targets. IUBMB Life 2008, 60(5):323-32. 10.1002/iub.47, 18421779.
72. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 2009, 486(2):95-102. 10.1016/j.abb.2009.01.018, 2749321, 19514131.
73. Hu KQ. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002, 139(4):234-43. 10.1067/mlc.2002.122281, 12024111.
74. Lim K, Han C, Dai Y, Shen M, Wu T. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther 2009, 8(11):3046-55. 10.1158/1535-7163.MCT-09-0551, 2783299, 19887546.
75. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, Moriwaki H. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 2009, 285(2):210-7. 10.1016/j.canlet.2009.05.019, 19520494.
76. Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res 2008, 14(9):2806-12. 10.1158/1078-0432.CCR-07-4708, 18451248.
77. Pascale RM, Simile MM, De Miglio MR, Nufris A, Daino L, Seddaiu MA, Rao PM, Rajalakshmi S, Sarma DS, Feo F. Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis 1995, 16(2):427-30. 10.1093/carcin/16.2.427, 7859377.
78. Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin JK, Lai GM, Hsieh CY, Cheng AL. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis 2000, 21(2):331-5. 10.1093/carcin/21.2.331, 10657978.
79. Maruyama S, Nagasue N, Dhar DK, Yamanoi A, El-Assal ON, Satoh K, Okita K. Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats. Clin Cancer Res 2001, 7(7):2096-104.
80. Kakizaki S, Takagi H, Fukusato T, Toyoda M, Horiguchi N, Sato K, Takayama H, Nagamine T, Mori M. Effect of alpha-tocopherol on hepatocarcinogenesis in transforming growth factor-alpha (TGF-alpha) transgenic mice treated with diethylnitrosamine. Int J Vitam Nutr Res 2001, 71(5):261-7. 10.1024/0300-9831.71.5.261, 11725690.
81. Basak R, Bhattacharya R, Chatterjee M. 1 alpha,25-Dihydroxyvitamin D(3) inhibits rat liver ultrastructural changes in diethylnitrosamine-initiated and phenobarbital promoted rat hepatocarcinogenesis. J Cell Biochem 2001, 81(2):357-67. 10.1002/1097-4644(20010501)81:2<357::AID-JCB1050>3.0.CO;2-Q, 11241675.
82. Qin G, Ning Y, Lotlikar PD. Chemoprevention of aflatoxin B1-initiated and carbon tetrachloride-promoted hepatocarcinogenesis in the rat by green tea. Nutr Cancer 2000, 38(2):215-22. 10.1207/S15327914NC382_11, 11525600.
83. Singh BN, Singh BR, Sarma BK, Singh HB. Potential chemoprevention of N-nitrosodiethylamine-induced hepatocarcinogenesis by polyphenolics from Acacia nilotica bark. Chem Biol Interact 2009, 181(1):20-8. 10.1016/j.cbi.2009.05.007, 19446540.
84. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008, 585(2-3):325-337. 10.1016/j.ejphar.2008.03.008, 18417116.
85. Matsumoto S, Jin M, Dewa Y, Nishimura J, Moto M, Murata Y, Shibutani M, Mitsumori K. Suppressive effect of Siraitia grosvenorii extract on dicyclanil-promoted hepatocellular proliferative lesions in male mice. J Toxicol Sci 2009, 34(1):109-18. 10.2131/jts.34.109, 19182440.
86. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 2009, 18(1):13-25. 10.1097/CEJ.0b013e3282f0c090, 19077560.
87. Murugan RS, Uchida K, Hara Y, Nagini S. Black tea polyphenols modulate xenobiotic-metabolizing enzymes, oxidative stress and adduct formation in a rat hepatocarcinogenesis model. Free Radic Res 2008, 42(10):873-84. 10.1080/10715760802506331, 18985486.
88. Ho YC, Liu CH, Chen CN, Duan KJ, Lin MT. Inhibitory effects of xanthohumol from hops (Humulus lupulus L.) on human hepatocellular carcinoma cell lines. Phytother Res 2008, 22(11):1465-8. 10.1002/ptr.2481, 18814205.
89. Kuroiwa-Trzmielina J, de Conti A, Scolastici C, Pereira D, Horst MA, Purgatto E, Ong TP, Moreno FS. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 2009, 124(11):2520-7. 10.1002/ijc.24212, 19195022.
90. Jagan S, Ramakrishnan G, Anandakumar P, Kamaraj S, Devaki T. Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat hepatocellular carcinoma. Mol Cell Biochem 2008, 319(1-2):51-9. 10.1007/s11010-008-9876-4, 18629614.
91. Glauert HP, Calfee-Mason K, Stemm DN, Tharappel JC, Spear BT. Dietary antioxidants in the prevention of hepatocarcinogenesis: A review. Mol Nutr Food Res 2010, 54(7):875-96. 10.1002/mnfr.200900482, 20512789.
92. Reeves PG, Nielsen FH, Fahey GC. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A diet. J Nutr 1993, 123:1939-1951.
93. Bjorkhem-Bergman L, Torndal UB, Eken S, Nystrom C, Capitanio A, Larsen EH, Björnstedt M, Eriksson LC. Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis 2005, 26:125-131. 10.1093/carcin/bgh290, 15459019.
94. Borbath I, Leclercq IA, Sempoux C, Abarca-Quinones J, Desaeger C, Horsmans Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chem Biol Interact 2010, 183(1):238-48. 10.1016/j.cbi.2009.10.011, 19874807.
95. Craxì A, Cammà C. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons. Dig Liver Dis 2010, 42:S287-92. 10.1016/S1590-8658(10)60518-X, 20547316.
96. Romeo R, Pol S, Berthelot P, Brechot C. Eradication of Hepatitis C Virus RNA after Alpha-Interferon Therapy. Annals of Internal Medicine 1994, 121:276-277.
97. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: Interferon-alpha Prevents the Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. J Viral Hepat 2010, 17(4):287-292. 10.1111/j.1365-2893.2009.01181.x, 19732321.
98. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL, . HALT-C Trial Investigators Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359(23):2429-41. 10.1056/NEJMoa0707615, 2606037, 19052125, HALT-C Trial Investigators.
99. Masuzaky R, Yoshida H, Omata M. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Oncology 2010, 78:17-23. 10.1159/000315225, 20616579.
100. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: Interferon-alpha Prevents the Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. J Viral Hepat 2010, 17(4):287-292. 10.1111/j.1365-2893.2009.01181.x, 19732321.
101. Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, Sezaki H, Akuta N, Suzuki Y, Suzuki F, Kumada H. A longterm glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci 2006, 51(3):603-9. 10.1007/s10620-006-3177-0, 16614974.
102. Group GHCSO Study on chemoprevention of hepatocellular carcinoma by ginseng: An introduction to the protocol. J Korean Med Sci 2001, S70-4. Group GHCSO.
103. Yu MW, Hsieh HH, Pan WH, Yang CS, Chen CJ. Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res 1995, 55(6):1301-5.
104. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334(24):1561-7. 10.1056/NEJM199606133342402, 8628336.
105. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999, 340(13):1046-7. 10.1056/NEJM199904013401315, 10189289.
106. Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Boil Trace Elem Res 1997, 56:117-124.
107. Yu S, Li W, Zhu Y, Yu WP, Hou C. Chemoprevention trial of human hepatitis with selenium supplementation in china. Biol Trace Elem Res 1989, 15-22. 10.1007/BF02919094, 2484394.
108. Ito Y, Suzuki K, Ishii J, Hishida H, Tamakoshi A, Hamajima N, Aoki K. A population-based follow-up study on mortality from cancer or cardiovascular disease and serum carotenoids, retinol and tocopherols in japans inhabitants. Asian Pac J Cancer Prev 2006, 7:533-546.
109. Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. Prediagnostic leel of serum retinol in relation to reduced risk of hepatocellular carcinoma. J Natl Cancer Inst 2006, 98:482-190. 10.1093/jnci/djj104, 16595784.
110. Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S, . JPHC Study Group Vegetable, fruit and antioxidant nutrient consumption and subsequent risk of hepatocellualr carcinoma: a prospective cohort study in Japan. Br J Cancer 2009, 100:181-184. 10.1038/sj.bjc.6604843, 2634663, 19127270, JPHC Study Group.